Literature DB >> 10692680

Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?

A L Martinelli1, R F Franco, M G Villanova, J F Figueiredo, M Secaf, M H Tavella, L N Ramalho, S Zucoloto, M A Zago.   

Abstract

It has been proposed that iron overload may adversely affect liver disease outcome. The recent identification of 2 mutations in the HFE gene related to hereditary haemochromatosis (Cys282Tyr and His63Asp) provided an opportunity to test whether they are associated with hepatic iron accumulation and the activity and severity of liver disease in hepatitis C virus (HCV) infection. We investigated the prevalence of HFE mutations in 135 male patients with chronic HCV hepatitis, and correlated genotype distribution with different parameters of iron status and the activity and severity of liver disease. Of these 135 patients, 6 (4.4%) carried Cys282Tyr and 32 (23.7%) carried His63Asp, frequencies which were similar to those observed in healthy controls. Serum iron levels and transferrin saturation (but not ferritin levels or liver iron content) were significantly higher in carriers than in non-carriers of HFE mutations. No difference was observed in serum ALT, AST and GGT levels between carriers and non-carriers. Finally, scores for necroinflammatory activity and fibrosis in the liver were significantly higher in HFE carriers than in non-carriers. Patients with chronic HCV infection carrying HFE mutations tend to present more evident body iron accumulation and a higher degree of necroinflammatory activity and fibrosis in the liver. HFE gene mutations might be an additional factor to be considered among those implicated in the determination of a worse prognosis of the liver disease in chronic HCV infection. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692680     DOI: 10.1159/000040991

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  14 in total

1.  Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection.

Authors:  Mark Thursz
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

2.  An unusual case of hemochromatosis in an African-American man: case report and review of the literature.

Authors:  David A Labowitz; Jennifer Bontreger; Albert D Min
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

3.  The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.

Authors:  D Thorburn; G Curry; R Spooner; E Spence; K Oien; D Halls; R Fox; E A B McCruden; R N M MacSween; P R Mills
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 4.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 5.  Manipulation of iron to determine survival: competition between host and pathogen.

Authors:  Nihay Laham; Rachel Ehrlich
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

Authors:  Sven G Gehrke; Wolfgang Stremmel; Inge Mathes; Hans-Dieter Riedel; Karin Bents; Birgit Kallinowski
Journal:  J Mol Med (Berl)       Date:  2003-10-14       Impact factor: 4.599

7.  The effect of iron depletion on chronic hepatitis C virus infection.

Authors:  Massimo Franchini; Giovanni Targher; Franco Capra; Martina Montagnana; Giuseppe Lippi
Journal:  Hepatol Int       Date:  2008-05-08       Impact factor: 6.047

8.  Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in sardinia.

Authors:  Margherita Sini; Orazio Sorbello; Alberto Civolani; Luigi Demelia
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

Review 9.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 10.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.